136 related articles for article (PubMed ID: 10188622)
21. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.
Thyss A; Milano G; Deville A; Manassero J; Renee N; Schneider M
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):843-7. PubMed ID: 3477462
[TBL] [Abstract][Full Text] [Related]
22. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
[TBL] [Abstract][Full Text] [Related]
23. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
[TBL] [Abstract][Full Text] [Related]
24. Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure.
Krackhardt A; Schwartz S; Korfel A; Thiel E
Leuk Lymphoma; 1999 Nov; 35(5-6):631-5. PubMed ID: 10609804
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
26. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult non-Hodgkin lymphoma.
Avivi I; Zuckerman T; Krivoy N; Efrati E
Leuk Lymphoma; 2014 Mar; 55(3):565-70. PubMed ID: 23829278
[TBL] [Abstract][Full Text] [Related]
28. [Leucovorin rescue after continuing infusion of high dose methotrexate].
Yang LH; Lu XT; Gu J; Hua Y; Zhao WH
Zhonghua Er Ke Za Zhi; 2005 May; 43(5):393-4. PubMed ID: 15924763
[No Abstract] [Full Text] [Related]
29. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
30. Plasma and urine levels of methotrexate and 7-hydroxymethotrexate in children with ALL during maintenance therapy with weekly oral methotrexate.
Skoglund KA; Söderhäll S; Beck O; Peterson C; Wennberg M; Hayder S; Björk O
Med Pediatr Oncol; 1994; 22(3):187-93. PubMed ID: 8272008
[TBL] [Abstract][Full Text] [Related]
31. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
32. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
33. [Serum monitoring of methotrexate (MTX) and 7-hydroxymethotrexate concentrations in patients treated with MTX using high-pressure liquid chromatography (HPLC) and comparison of serum MTX levels between HPLC method and fluorescence polarization immunoassay (FPIA)].
Sakamoto S; Matsuhisa T; Miyoshi K; Naruse R; Urayama H; Shimokawa T; Okabe K; Toki H; Motoi M; Moriwaki S
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1119-25. PubMed ID: 2053771
[TBL] [Abstract][Full Text] [Related]
34. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
35. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
[TBL] [Abstract][Full Text] [Related]
36. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.
Yang CH; Yang LJ; Jaing TH; Chan HL
Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
38. Carboxypeptidase G2 rescue after high-dose methotrexate.
DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
[TBL] [Abstract][Full Text] [Related]
39. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
40. 5-fluorouracil modulates the toxicity of high dose methotrexate.
White RM
J Clin Pharmacol; 1995 Dec; 35(12):1156-65. PubMed ID: 8750366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
